MTOR S2215F

CI-VAR-00004024Explore in graph →CIViC 2715

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Solid Neoplasm1
MTOR S2215F	Sirolimus	Predictive	D	Supports Sensitivity Response	3	submitted	EID7326 Sequencing data from 22 human kidney cancer cases was used to identify the activating mechanisms conferred by mTOR mutations. Cells that expressed activating mTOR mutants were sensitive to rapamycin t… (full text at CIViC) PMID 27482884 · Xu et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.